Introduction JAK-inhibitors (JAK-i) represent an effective treatment in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Oral glucocorticoids (OGC) are commonly used in combination with JAK-i to reach therapeutic target. we aimed to assess, in a real-life setting, the reduction of OGC dose during JAK-i treatment in active RA and PsA patients.methods we prospectively enrolled 103 patients (88 RA, 15 PsA) treated with JAK-i: 24% bio-na & iuml;ve (b-na & iuml;ve), 76% bDMARD-insufficient responders (bDMARD-IR) and 40% difficult to treat (D2T), defined as failure of >= 2 bDMARDs with different mechanism of action. disease activity (DAS28 and DAPSA, VAS-pain, GH) and OGC dose was collected at baseline and after 3, 6 and 12 months (T3, T6, T12) of treatment. results In all the cohort and in b-na & iuml;ve patients we reported a reduction of OGC dose at all time-points; bDMARD-IR patients were able to reduce OGC dose at T3 and T12; D2T ones only at T3. we reported an improvement of disease activity and withdrawal of OGC as early as three months of therapy, at all time-points, regardless of line of bDMARD treatment.conclusion chronic OGC may cause detrimental bone, metabolic, cardiovascular side effects and infections; therefore JAK-i steroid-sparing effect may be beneficial for patients in long-term treatment.

Conigliaro, P., Minerba, C., Vendola, A., Fiannacca, L., Triggianese, P., Kroegler, B., et al. (2024). The steroid-sparing effect of JAK inhibitors across multiple patient populations. FRONTIERS IN IMMUNOLOGY, 15 [10.3389/fimmu.2024.1376476].

The steroid-sparing effect of JAK inhibitors across multiple patient populations

Conigliaro P.;Minerba C.;Vendola A.;Fiannacca L.;Triggianese P.;Greco E.;Bergamini A.;Chimenti M. S.
2024-01-01

Abstract

Introduction JAK-inhibitors (JAK-i) represent an effective treatment in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Oral glucocorticoids (OGC) are commonly used in combination with JAK-i to reach therapeutic target. we aimed to assess, in a real-life setting, the reduction of OGC dose during JAK-i treatment in active RA and PsA patients.methods we prospectively enrolled 103 patients (88 RA, 15 PsA) treated with JAK-i: 24% bio-na & iuml;ve (b-na & iuml;ve), 76% bDMARD-insufficient responders (bDMARD-IR) and 40% difficult to treat (D2T), defined as failure of >= 2 bDMARDs with different mechanism of action. disease activity (DAS28 and DAPSA, VAS-pain, GH) and OGC dose was collected at baseline and after 3, 6 and 12 months (T3, T6, T12) of treatment. results In all the cohort and in b-na & iuml;ve patients we reported a reduction of OGC dose at all time-points; bDMARD-IR patients were able to reduce OGC dose at T3 and T12; D2T ones only at T3. we reported an improvement of disease activity and withdrawal of OGC as early as three months of therapy, at all time-points, regardless of line of bDMARD treatment.conclusion chronic OGC may cause detrimental bone, metabolic, cardiovascular side effects and infections; therefore JAK-i steroid-sparing effect may be beneficial for patients in long-term treatment.
2024
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/16
English
JAK inhibitors
glucocorticoids
prognostic factors
psoriatic arthritis
retention rate
rheumatoid arthritis
Conigliaro, P., Minerba, C., Vendola, A., Fiannacca, L., Triggianese, P., Kroegler, B., et al. (2024). The steroid-sparing effect of JAK inhibitors across multiple patient populations. FRONTIERS IN IMMUNOLOGY, 15 [10.3389/fimmu.2024.1376476].
Conigliaro, P; Minerba, C; Vendola, A; Fiannacca, L; Triggianese, P; Kroegler, B; Greco, E; Bergamini, A; Chimenti, Ms
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/363404
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 3
social impact